ELK1 is an ETS-domain transcription factor that binds purine-rich DNA sequences and forms ternary complexes with serum response factor (SRF) at serum response elements to activate immediate-early genes such as FOS and IER2 in response to ERK and JNK signaling. Beyond its canonical activating role, ELK1 possesses context-dependent repressive activities at specific genomic loci. In hematopoiesis, ELK1 isoforms regulate the balance between neutrophil and erythroid differentiation; alpha-lipoic acid targets ELK1 to promote erythroid lineage commitment in CD34+ hematopoietic stem progenitor cells 1. ELK1 is dysregulated across multiple solid tumors including lung, breast, prostate, and colorectal cancers, where elevated expression drives proliferation, migration, epithelial-to-mesenchymal transition, and metastasis 2. In colorectal cancer liver metastasis, ELK1 participates in a CCL20/CCR6/ERK1/2/ELK1/miR-181a-5p positive feedback loop that remodels the tumor microenvironment 3. In prostate cancer, disruption of the ELK1-androgen receptor complex represents a validated therapeutic strategy, as ELK1 tethers AR to chrX to coactivate cell proliferation genes 4. Beyond oncology, ELK1 dysfunction correlates with heroin abuse and associates with OPRM1 polymorphism in striatal opioid signaling 5, and ELK1 is functionally required for CHD8-mediated chrX activation in human neurons, implicating it in autism spectrum disorder pathogenesis 6.